News
Biofrontera Inc. Reports First Quarter 2023 Financial Results and Provides a Business Update
Conference call begins at 8:30 a.m. Eastern time todayWOBURN, MA / ACCESSWIRE / May 12, 2023 / Biofrontera Inc. (Nasdaq:BFRI) (the "Company"), a biopharmaceutical company specializing in the commercialization of dermatologic products, today reported financial results...
Biofrontera Inc. Announces Resignation of CEO
Executive Chairman Hermann Luebbert to Assume CEO Responsibilities, Reaffirms the Company's Strategic Plan and 2023 Commercial GoalsWOBURN, MA / ACCESSWIRE / May 12, 2023 / Biofrontera Inc. (Nasdaq:BFRI) (the "Company"), a biopharmaceutical company specializing in the...
Biofrontera Inc. Announces New Secured Line of Credit up to $6.5 Million
WOBURN, MA / ACCESSWIRE / May 11, 2023 / Biofrontera Inc. (NASDAQ:BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, today announced that it has entered into a $6.5 million secured line of credit with MidCap Business...
Biofrontera Collaborates with The Skin Cancer Foundation to Raise Awareness of Skin Cancer Prevention
WOBURN, MA / ACCESSWIRE / May 9, 2023 / Biofrontera Inc. (NASDAQ:BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, today announced that as part of several Skin Cancer Awareness Month activities taking place throughout...
Biofrontera Inc. to Report First Quarter 2023 Financial Results on May 12, 2023
WOBURN, MA / ACCESSWIRE / April 28, 2023 / Biofrontera Inc. (Nasdaq:BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, today announced that it will report financial results for the three months ended March 31, 2023 on...
Biofrontera Inc. Announces Last Patient Out in Phase I Study to Evaluate Safety and Tolerability in Treating Actinic Keratosis Using 3 Tubes of Ameluz®
WOBURN, MA / ACCESSWIRE / April 26, 2023 / Biofrontera Inc. (NASDAQ:BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, today announced that that the last patient in a Phase I study to evaluate the safety and...
Biofrontera Inc. Makes Transformative Investment in Its’ Dermatology Salesforce
WOBURN, MA / ACCESSWIRE / March 27, 2023 / Biofrontera Inc. (NASDAQ:BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, today announced that it is executing on the company's stated plans to invest in and meaningfully...
Biofrontera Inc. to Attend 2023 American Academy of Dermatology Annual Meeting
Providing live demonstrations of a PDT procedure using the RhodoLED® lamp at booth #2224WOBURN, MA / ACCESSWIRE / March 17, 2023 / Biofrontera Inc. (NASDAQ:BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, today...
CORRECTING AND REPLACING: Biofrontera Inc. Reports Fourth Quarter and Record Full-year 2022 Financial Results
This press release corrects and replaces the press release published on 3/8/2023 at 4:03:00 PM ET, as the Adjusted EBITDA Reconciliation table was not included in all previously posted versions of the press release.WOBURN, MA / ACCESSWIRE / March 9, 2023 /...
Biofrontera Inc. Reports Fourth Quarter and Record Full-year 2022 Financial Results
WOBURN, MA / ACCESSWIRE / March 8, 2023 / Biofrontera, Inc. (NASDAQ:BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, today announced financial results for the three and twelve months ended December 31,...